NBSE
- NeuBase Therapeutics, Inc.
()
Overview
Company Summary
NeuBase Therapeutics, Inc. (NBSE) is a biotechnology company that focuses on developing therapies using its proprietary peptide-nucleic acid antisense oligonucleotide (PNAs) platform. The company's innovative technology enables precise manipulation of RNA, which plays a pivotal role in the regulation of gene expression and the production of proteins.
NBSE utilizes its PNA platform to design and develop next-generation precision medicines to target various genetic diseases. By specifically targeting the RNA responsible for these diseases, NeuBase aims to produce therapeutic outcomes by directly modulating gene expression.
The PNA molecules developed by NeuBase differ from traditional oligonucleotides in their structure, which enhances their target binding specificity and efficiency. This approach allows the company to address the limitations faced by existing gene therapies and gene-editing technologies.
NeuBase Therapeutics' pipeline includes programs targeting specific diseases such as Huntington's disease, myotonic dystrophy, and additional genetic disorders. By leveraging their proprietary platform, the company aims to create breakthrough therapies to potentially transform the treatment landscape for patients with genetic conditions.
In summary, NeuBase Therapeutics focuses on the development of precision medicines using its PNA platform to target RNA and modulate gene expression. Their goal is to address the unmet medical needs of patients with genetic diseases by advancing innovative therapies.